Breast cancer cell–derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0.666. It has been cited 84 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.666
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institute of Health
Grant: R01CA218578,R21CA216230
National Institutes of Health
Grant: 3R01CA218578-05S1
Emodin as a chemopreventive agent for breast cancer
National Institutes of Health
Grant: 5R21CA216230-02
Impact of macrophage PCSK9 on breast cancer
NCI NIH HHS
Grant: R01 CA218578
NCI NIH HHS
Grant: R21 CA216230
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals